Larry Robbins Billionaire Investor Shares Insights

Larry Robbins is a renowned billionaire investor who has made a name for himself in the financial world. He is the founder and CEO of Glenview Capital Management, a hedge fund that has been around since 2000.

Robbins' investment strategy focuses on deep value investing, which involves looking for undervalued companies with strong fundamentals. He has a keen eye for spotting potential in companies that others may overlook.

One of Robbins' key strengths is his ability to identify companies with strong balance sheets and competitive advantages. This approach has helped him achieve impressive returns for his investors over the years.

After graduating, Larry Robbins worked at Gleacher & Company, a merger and advisory boutique in New York.

He joined Leon Cooperman at Omega Advisors after three years at Gleacher.

Robbins spent six years as an analyst and partner at Omega Advisors on their US equity long/short team.

Robbins left Omega to start Glenview Capital Management in 2000, named after the suburban Chicago hockey area where he started playing hockey at age five.

In 2012, he made a successful bet by investing in hospital companies that he thought would benefit from Obamacare.

Unlike most hedge funds, Robbins is known for holding stocks for years and not employing stop-losses.

Robbins is currently the firm's CEO and portfolio manager.

Larry Robbins, the hedge fund mogul, has been actively involved in various activities as a hedge fund manager. He is the founder of Glenview Capital Management, a firm that specializes in healthcare investments.

Robbins has a significant stake in CVS, a struggling drugstore chain, and has met with executives to present a turnaround plan. He believes in the company's potential and is confident that his ideas can boost profitability.

As a seasoned hedge fund manager, Robbins has experienced his fair share of ups and downs. He has made big bets on healthcare companies, including hospital chain HCA Healthcare and health insurers Humana and Anthem. His stock portfolio continues to reflect these big bets.

Robbins has also been vocal about his support for Dow Chemical, a company that is set to merge with DuPont. He has expressed his desire for Dow CEO Andrew Liveris to retire quickly and for changes to the current breakup plan for the company.

Check this out: John Paulson Big Short

In the world of hedge funds, some investments stand out from the rest. One notable investment is in private equity, with many hedge funds allocating a significant portion of their assets to this sector.

Hedge funds like Renaissance Technologies have invested heavily in private equity, with a focus on mid-market deals.

Another notable investment area is in real estate, with hedge funds like Oaktree Capital Management allocating a substantial portion of their assets to this sector.

Explore further: Early History of Private Equity

Larry Robbins, a hedge fund billionaire, is staging his latest trading comeback, posting solid returns for the last 12 months.

He returned 14.8% in the first half of 2017, outperforming the S&P 500 index which returned 9.3% in the same period.

Glenview Capital Management, Robbins' hedge fund firm, has seen its assets under management rise back to $11.5 billion.

Robbins' main hedge fund, Glenview Capital Partners, posted losses of 18.1% in 2015 and then fell by 2.6% in 2016.

Readers also liked: Stephen Mandel (hedge Fund Manager)

He started to turn things around after posting double digit losses in the first half of 2016, and his firm's assets under management dipped to around $10 billion.

Robbins' stock portfolio continues to reflect big bets on healthcare, with his biggest U.S. stock positions this year being hospital company HCA Healthcare, and health insurers Humana and Anthem.

Anthem is up 28% in 2017, while HCA Healthcare and Humana are also performing well.

Robbins also has a sizable position in Dow Chemical, a stock that has risen by 15.5% this year, ahead of its merger with DuPont.

He has been vocal about wanting Dow CEO Andrew Liveris to retire quickly and changes to the current breakup plan for the company.

For another approach, see: Jesse Livermore Stock Trader